tradingkey.logo
搜尋
市場行情
新聞
分析
交易工具
投資課堂
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
搜尋

Akoustis Technologies Ord Shs

AKTS
添加自選
18.090USD
+0.250+1.40%
收盤 04/15, 16:00（美東）報價延遲15分鐘
2.80B總市值
虧損本益比TTM

Akoustis Technologies Ord Shs

18.090
+0.250+1.40%
概覽財務分析公司

概覽

財務

分析

公司

關於 Akoustis Technologies Ord Shs 公司

Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.

Akoustis Technologies Ord Shs簡介

公司代碼AKTS
公司名稱Aktis Oncology Inc
上市日期Jan 09, 2026
CEORoden (Matthew)
員工數量117
證券類型Ordinary Share
年結日Jan 09
公司地址17 Drydock Avenue
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02210
電話13026587581
網址https://www.aktisoncology.com/
公司代碼AKTS
上市日期Jan 09, 2026
CEORoden (Matthew)

Akoustis Technologies Ord Shs公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
Dr. Andrew Levin, M.D., Ph.D.
Dr. Andrew Levin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mr. Lloyd M. Segal
Mr. Lloyd M. Segal
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 1月10日 週六
單位: USD更新時間: 1月10日 週六
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Asia
5.84M
64.74%
Americas
2.43M
26.95%
Europe
750.00K
8.31%
業務
地區
由於公司未披露，未能獲取相關數據

股東統計

更新時間: 2 小時前
更新時間: 2 小時前
持股股東
股東類型
持股股東
持股股東
佔比
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
其他
47.76%
持股股東
持股股東
佔比
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
其他
47.76%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
28.97%
Corporation
11.88%
Venture Capital
10.92%
Investment Advisor
2.21%
Individual Investor
0.40%
其他
45.62%

機構持股

更新時間: 1月10日 週六
更新時間: 1月10日 週六
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
184
21.93M
41.01%
-7.10M
2025Q4
188
74.33K
0.05%
-32.41M
2025Q3
209
74.33K
0.05%
-35.90M
2025Q2
236
74.33K
0.05%
-41.95M
2025Q1
251
315.89K
0.20%
-42.44M
2024Q4
266
839.61K
0.54%
-43.07M
2024Q3
283
21.16M
13.70%
-24.03M
2024Q2
288
25.38M
23.18%
-30.85M
2024Q1
283
43.24M
43.52%
-1.29M
2023Q4
287
31.11M
40.06%
-14.76M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
MPM BioImpact LLC
10.26M
19.21%
+10.26M
--
Jan 12, 2026
Eli Lilly and Company
6.34M
11.88%
+6.34M
--
Jan 12, 2026
VV Manager LLC
5.83M
10.92%
+5.83M
--
Jan 12, 2026
EcoR1 Capital, LLC
4.82M
9.03%
+4.82M
--
Jan 12, 2026
Fidelity Management & Research Company LLC
555.55K
1.04%
+555.55K
--
Jan 31, 2026
Wellington Management Company, LLP
208.41K
0.39%
+208.41K
--
Jan 31, 2026
Driehaus Capital Management, LLC
143.14K
0.27%
+143.14K
--
Jan 31, 2026
Feldman (Paul L. Ph.D.)
118.28K
0.22%
+118.28K
--
Jan 09, 2026
查看更多

持股ETF

更新時間: 1月10日 週六
更新時間: 1月10日 週六
機構名稱
佔比
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Proshares Ultra Russell 2000
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI